A phase II trial of Lu radiolabeled monoclonal antibody HuJ591-GS (Lu-J591) [MLN 591RL] in patients with metastatic androgen-independent prostate cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Oct 2005 New trial record.